活检前血清PSA复测是否总是必要?个体与分析因素对活检转诊决策影响的研究
该研究纳入333例前列腺癌筛查患者,在中位3.9个月后重复PSA检测(Roche Cobas系统)再行活检。前列腺癌组与无癌组基线PSA阳性率相近(84.8% vs 83.9%,P=0.931),复测后转为正常的比例极低(0.9% vs 3.7%,P=0.286),约31%患者PSA显著升高。结论认为在相同免疫分析和受控分析条件下,PSA阳性结果复测后绝大多数得到确认,分析因素和个体内变异均不足以支持活检前常规复测PSA。
要点
- 前列腺癌与无癌患者基线PSA阳性率无显著差异(84.8% vs 83.9%)。
- 复测后PSA转为正常的比例极低,前列腺癌组仅0.9%。
- 分析因素与个体内变异不足以支持活检前常规复测PSA。
核心结论
- 在相同免疫分析和受控分析条件下,PSA阳性结果复测后绝大多数筛查患者得到确认。
- 分析因素和个体内变异均不足以支持活检转诊前常规复测PSA。
研究设计与样本
- 研究纳入333例接受前列腺癌筛查的患者,在中位3.9个月后重复PSA检测(Roche Cobas系统),随后进行活检。
- 采用多元回归模型评估患者特征对PSA结果及随时间变化的影响。
主要发现
- 前列腺癌患者132例(40.7%),无癌患者192例(59.3%)。
- 两组基线PSA阳性率分别为84.8%和83.9%(P=0.931)。
- 复测后转为正常PSA的比例分别为0.9%和3.7%(P=0.286)。
- 分别有31.1%和31.3%的患者复测后PSA显著升高(P=0.426)。
- 年龄是混杂因素,老年前列腺癌患者PSA升高且与病理分级相关;无癌患者中约1/3存在腺体炎症,与较高PSA浓度相关。
临床怎么用
- 在相同免疫分析和受控分析条件下,PSA阳性结果复测后大多确认,可考虑减少活检前不必要的PSA复测。
- 应关注年龄和前列腺炎症对PSA水平的影响,综合评估活检转诊决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We investigated factors influencing pre-biopsy prostate-specific antigen (PSA) retesting as recommended by clinical guidelines. MATERIALS AND METHODS: 333 patients screened for prostate cancer (PCa) repeated PSA (Roche Cobas systems) after a median of 3.9 months, before performing biopsy. Multiple regression models were used to assess effects of patients' characteristics on PSA results and changes over time. RESULTS: PCa [n = 132 (40.7%)] and cancer-free [n = 192 (59.3%)] patients had similar rate of PSA positive results at baseline (84.8% vs. 83.9%, P = 0.931). Their rate of reversion to normal PSA after retesting was negligible (0.9% in PCa and 3.7% in PCa-free patients, P = 0.286). 31.1% of PCa and 31.3% of cancer-free patients (P = 0.426) showed a significant PSA increase after retesting. Age was a confounder since not only PSA increased in older PCa patients, but it was also related to PCa histological grade, in turn associated to PSA increase. In PCa-free patients, glandular inflammation, present in 1/3 of subjects, was also associated to higher PSA concentrations. CONCLUSION: When obtained with the same immunoassay under controlled analytical conditions, a PSA positive result is confirmed after retesting in the great majority of screened patients. Neither analytical factors nor intraindividual variability appeared to justify PSA retesting before biopsy referral.
引用
- Ferraro S, Bussetti M, Rossi RS, et al. Is pre-biopsy serum prostate specific antigen retesting always justified? A study of the influence of individual and analytical factors on decision making for biopsy referral. Clin Chim Acta. 2021. PMID: 33524337. doi:10.1016/j.cca.2021.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。